Information de reference pour ce titreAccession Number: | 00043605-201608000-00010.
|
Author: | Hytonen, Jarkko; Leppanen, Olli; Braesen, Jan Hinrich; Schunck, Wolf-Hagen; Mueller, Dominik; Jung, Friedrich; Mrowietz, Christoph; Jastroch, Martin; von Bergwelt-Baildon, Michael; Kappert, Kai; Heuser, Arnd; Drenckhahn, Jorg-Detlef; Pieske, Burkert; Thierfelder, Ludwig; Yla-Herttuala, Seppo; Blaschke, Florian
|
Institution: | From the Department of Molecular Medicine, A.I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland (J.H., S.Y.-H.); Centre for R&D, Uppsala University/County Council of Gaevleborg, Gaevle, Sweden (O.L.); Institute for Pathology, University Clinic of Schleswig-Holstein, Campus Kiel, Kiel, Germany (J.H.B.); Max-Delbruck Center for Molecular Medicine, Berlin, Germany (W.-H.S., D.M., A.H., J.-D.D., L.T., F.B.); Department of Cardiology (B.P., F.B.) and Center for Cardiovascular Research/CCR, Institute of Laboratory Medicine Clinical Chemistry and Pathobiochemistry (K.K.), Charite-Universitaetsmedizin Berlin, Berlin, Germany; Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies (BCRT), Helmholtz-Zentrum Geesthacht, Teltow, Germany (F.J., C.M.); Institute for Diabetes and Obesity, Helmholtz Zentrum Muenchen, Munich, German Research Center for Environmental Health, Germany (M.J.); and Cologne Interventional Immunology, University Hospital of Cologne, Cologne, Germany (M.v.B.-B.).
|
Title: | |
Source: | Arteriosclerosis, Thrombosis & Vascular Biology. 36(8):1534-1548, August 2016.
|
Abstract: | Objective-: Drug-eluting coronary stents reduce restenosis rate and late lumen loss compared with bare-metal stents; however, drug-eluting coronary stents may delay vascular healing and increase late stent thrombosis. The peroxisome proliferator-activated receptor-delta (PPAR[delta]) exhibits actions that could favorably influence outcomes after drug-eluting coronary stents placement.
Approach and Results-: Here, we report that PPAR[delta] ligand-coated stents strongly reduce the development of neointima and luminal narrowing in a rabbit model of experimental atherosclerosis. Inhibition of inflammatory gene expression and vascular smooth muscle cell (VSMC) proliferation and migration, prevention of thrombocyte activation and aggregation, and proproliferative effects on endothelial cells were identified as key mechanisms for the prevention of restenosis. Using normal and PPAR[delta]-depleted VSMCs, we show that the observed effects of PPAR[delta] ligand GW0742 on VSMCs and thrombocytes are PPAR[delta] receptor dependent. PPAR[delta] ligand treatment induces expression of pyruvate dehydrogenase kinase isozyme 4 and downregulates the glucose transporter 1 in VSMCs, thus impairing the ability of VSMCs to provide the increased energy demands required for growth factor-stimulated proliferation and migration.
Conclusions-: In contrast to commonly used drugs for stent coating, PPAR[delta] ligands not only inhibit inflammatory response and proliferation of VSMCs but also prevent thrombocyte activation and support vessel re-endothelialization. Thus, pharmacological PPAR[delta] activation could be a promising novel strategy to improve drug-eluting coronary stents outcomes.
(C) 2016 American Heart Association, Inc.
|
Author Keywords: | blood platelets; coronary in-stent restenosis; endothelial cells; peroxisome proliferator-activated receptors; vascular smooth muscle cells.
|
References: | 1. Roger VL, Go AS, Lloyd-Jones DM, et al.American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012;125:188-197 doi: 10.1161/CIR.0b013e3182456d46
2. Thom T, Haase N, Rosamond W, et al.American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85-151 doi: 10.1161/CIRCULATIONAHA.105.171600
3. Inoue T, Node K. Molecular basis of restenosis and novel issues of drug-eluting stents. Circ J. 2009;73:615-621
4. Babinska A, Markell MS, Salifu MO, Akoad M, Ehrlich YH, Kornecki E. Enhancement of human platelet aggregation and secretion induced by rapamycin. Nephrol Dial Transplant. 1998;13:3153-3159
5. Granada JF, Alviar CL, Wallace-Bradley D, Osteen M, Dave B, Tellez A, Win HK, Kleiman NS, Kaluza GL, Lev EI. Patterns of activation and deposition of platelets exposed to the polymeric surface of the paclitaxel eluting stent. J Thromb Thrombolysis. 2010;29:60-69 doi: 10.1007/s11239-009-0348-9
6. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193-202 doi: 10.1016/j.jacc.2006.03.042
7. Mack CP. Signaling mechanisms that regulate smooth muscle cell differentiation. Arterioscler Thromb Vasc Biol. 2011;31:1495-1505 doi: 10.1161/ATVBAHA.110.221135
8. Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. A cascade model for restenosis. A special case of atherosclerosis progression. Circulation. 1992;86(6 suppl):III47-III52
9. Yang X, Thomas DP, Zhang X, Culver BW, Alexander BM, Murdoch WJ, Rao MN, Tulis DA, Ren J, Sreejayan N. Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation. Arterioscler Thromb Vasc Biol. 2006;26:85-90 doi: 10.1161/01.ATV.0000191635.00744.b6
10. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029-1033 doi: 10.1126/science.1160809
11. Perez J, Hill BG, Benavides GA, Dranka BP, Darley-Usmar VM. Role of cellular bioenergetics in smooth muscle cell proliferation induced by platelet-derived growth factor. Biochem J. 2010;428:255-267 doi: 10.1042/BJ20100090
12. Barish GD, Narkar VA, Evans RM. PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest. 2006;116:590-597 doi: 10.1172/JCI27955
13. Bishop-Bailey D, Bystrom J. Emerging roles of peroxisome proliferator-activated receptor-beta/delta in inflammation. Pharmacol Ther. 2009;124:141-150 doi: 10.1016/j.pharmthera.2009.06.011
14. Bojic LA, Huff MW. Peroxisome proliferator-activated receptor [delta]: a multifaceted metabolic player. Curr Opin Lipidol. 2013;24:171-177 doi: 10.1097/MOL.0b013e32835cc949
15. Bays HE, Schwartz S, Littlejohn T III, Kerzner B, Krauss RM, Karpf DB, Choi YJ, Wang X, Naim S, Roberts BK. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J Clin Endocrinol Metab. 2011;96:2889-2897 doi: 10.1210/jc.2011-1061
16. Olson EJ, Pearce GL, Jones NP, Sprecher DL. Lipid effects of peroxisome proliferator-activated receptor-[delta] agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome. Arterioscler Thromb Vasc Biol. 2012;32:2289-2294 doi: 10.1161/ATVBAHA.112.247890
17. Marmur JD, Poon M, Rossikhina M, Taubman MB. Induction of PDGF-responsive genes in vascular smooth muscle. Implications for the early response to vessel injury. Circulation. 1992;86(6 suppl):III53-III60
18. Doran AC, Meller N, McNamara CA. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 2008;28:812-819 doi: 10.1161/ATVBAHA.107.159327
19. Lim HJ, Lee S, Park JH, Lee KS, Choi HE, Chung KS, Lee HH, Park HY. PPAR delta agonist L-165041 inhibits rat vascular smooth muscle cell proliferation and migration via inhibition of cell cycle. Atherosclerosis. 2009;202:446-454 doi: 10.1016/j.atherosclerosis.2008.05.023
20. Burdick AD, Bility MT, Girroir EE, Billin AN, Willson TM, Gonzalez FJ, Peters JM. Ligand activation of peroxisome proliferator-activated receptor-beta/delta(PPARbeta/delta) inhibits cell growth of human N/TERT-1 keratinocytes. Cell Signal. 2007;19:1163-1171 doi: 10.1016/j.cellsig.2006.12.007
21. Romanowska M, al Yacoub N, Seidel H, Donandt S, Gerken H, Phillip S, Haritonova N, Artuc M, Schweiger S, Sterry W, Foerster J. PPARdelta enhances keratinocyte proliferation in psoriasis and induces heparin-binding EGF-like growth factor. J Invest Dermatol. 2008;128:110-124 doi: 10.1038/sj.jid.5700943
22. Han S, Ritzenthaler JD, Zheng Y, Roman J. PPARbeta/delta agonist stimulates human lung carcinoma cell growth through inhibition of PTEN expression: the involvement of PI3K and NF-kappaB signals. Am J Physiol Lung Cell Mol Physiol. 2008;294:L1238-L1249 doi: 10.1152/ajplung.00017.2008
23. Rubin LJ, Magliola L, Feng X, Jones AW, Hale CC. Metabolic activation of AMP kinase in vascular smooth muscle. J Appl Physiol (1985). 2005;98:296-306 doi: 10.1152/japplphysiol.00075.2004
24. Klip A, Tsakiridis T, Marette A, Ortiz PA. Regulation of expression of glucose transporters by glucose: a review of studies in vivo and in cell cultures. FASEB J. 1994;8:43-53
25. Schober A. Chemokines in vascular dysfunction and remodeling. Arterioscler Thromb Vasc Biol. 2008;28:1950-1959 doi: 10.1161/ATVBAHA.107.161224
26. Lee CH, Chawla A, Urbiztondo N, Liao D, Boisvert WA, Evans RM, Curtiss LK. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science. 2003;302:453-457 doi: 10.1126/science.1087344
27. McNicol A, Israels SJ. Beyond hemostasis: the role of platelets in inflammation, malignancy and infection. Cardiovasc Hematol Disord Drug Targets. 2008;8:99-117
28. Akbiyik F, Ray DM, Gettings KF, Blumberg N, Francis CW, Phipps RP. Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes. Blood. 2004;104:1361-1368 doi: 10.1182/blood-2004-03-0926
29. Ali FY, Davidson SJ, Moraes LA, Traves SL, Paul-Clark M, Bishop-Bailey D, Warner TD, Mitchell JA. Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARbeta. FASEB J. 2006;20:326-328 doi: 10.1096/fj.05-4395fje
30. Ray DM, Spinelli SL, Pollock SJ, Murant TI, O'Brien JJ, Blumberg N, Francis CW, Taubman MB, Phipps RP. Peroxisome proliferator-activated receptor gamma and retinoid X receptor transcription factors are released from activated human platelets and shed in microparticles. Thromb Haemost. 2008;99:86-95 doi: 10.1160/TH07-05-0328
31. Mrowietz C, Franke RP, Seyfert UT, Park JW, Jung F. Haemocompatibility of polymer-coated stainless steel stents as compared to uncoated stents. Clin Hemorheol Microcirc. 2005;32:89-103
32. Liou JY, Lee S, Ghelani D, Matijevic-Aleksic N, Wu KK. Protection of endothelial survival by peroxisome proliferator-activated receptor-delta mediated 14-3-3 upregulation. Arterioscler Thromb Vasc Biol. 2006;26:1481-1487 doi: 10.1161/01.ATV.0000223875.14120.93
33. Piqueras L, Reynolds AR, Hodivala-Dilke KM, Alfranca A, Redondo JM, Hatae T, Tanabe T, Warner TD, Bishop-Bailey D. Activation of PPARbeta/delta induces endothelial cell proliferation and angiogenesis. Arterioscler Thromb Vasc Biol. 2007;27:63-69 doi: 10.1161/01.ATV.0000250972.83623.61
34. Park JH, Lee KS, Lim HJ, Kim H, Kwak HJ, Park HY. The PPAR[delta] ligand L-165041 inhibits VEGF-induced angiogenesis, but the antiangiogenic effect is not related to PPAR[delta]. J Cell Biochem. 2012;113:1947-1954 doi: 10.1002/jcb.24063
35. Guagliumi G, Ikejima H, Sirbu V, Bezerra H, Musumeci G, Lortkipanidze N, Fiocca L, Tahara S, Vassileva A, Matiashvili A, Valsecchi O, Costa M. Impact of drug release kinetics on vascular response to different zotarolimus-eluting stents implanted in patients with long coronary stenoses: the LongOCT study (Optical Coherence Tomography in Long Lesions). JACC Cardiovasc Interv. 2011;4:778-785 doi: 10.1016/j.jcin.2011.04.007
36. Palmaz JC TF, Schatz RA, Alvarado R, Rees C, Garcia FS. Early endothelialization of balloon-expandable stents: experimental observations. J Intervent Radiol. 1988;3:119-124
37. Nandhikonda P, Yasgar A, Baranowski AM, et al. Peroxisome proliferation-activated receptor [delta] agonist GW0742 interacts weakly with multiple nuclear receptors, including the vitamin D receptor. Biochemistry. 2013;52:4193-4203 doi: 10.1021/bi400321p
38. Kostadinova R, Montagner A, Gouranton E, Fleury S, Guillou H, Dombrowicz D, Desreumaux P, Wahli W. GW501516-activated PPAR[beta]/[delta] promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation. Cell Biosci. 2012;2:34 doi: 10.1186/2045-3701-2-34
39. Zhang J, Fu M, Zhu X, Xiao Y, Mou Y, Zheng H, Akinbami MA, Wang Q, Chen YE. Peroxisome proliferator-activated receptor delta is up-regulated during vascular lesion formation and promotes post-confluent cell proliferation in vascular smooth muscle cells. J Biol Chem. 2002;277:11505-11512 doi: 10.1074/jbc.M110580200
40. Wurch T, Junquero D, Delhon A, Pauwels J. Pharmacological analysis of wild-type alpha, gamma and delta subtypes of the human peroxisome proliferator-activated receptor. Naunyn Schmiedebergs Arch Pharmacol. 2002;365:133-140 doi: 10.1007/s00210-001-0504-z
41. Nakamura MT, Yudell BE, Loor JJ. Regulation of energy metabolism by long-chain fatty acids. Prog Lipid Res. 2014;53:124-144 doi: 10.1016/j.plipres.2013.12.001
42. Brunmair B, Staniek K, Dorig J, Szocs Z, Stadlbauer K, Marian V, Gras F, Anderwald C, Nohl H, Waldhausl W, Furnsinn C. Activation of PPAR-delta in isolated rat skeletal muscle switches fuel preference from glucose to fatty acids. Diabetologia. 2006;49:2713-2722 doi: 10.1007/s00125-006-0357-6
43. Kramer DK, Al-Khalili L, Guigas B, Leng Y, Garcia-Roves PM, Krook A. Role of AMP kinase and PPARdelta in the regulation of lipid and glucose metabolism in human skeletal muscle. J Biol Chem. 2007;282:19313-19320 doi: 10.1074/jbc.M702329200
44. Stone JD, Narine A, Shaver PR, Fox JC, Vuncannon JR, Tulis DA. AMP-activated protein kinase inhibits vascular smooth muscle cell proliferation and migration and vascular remodeling following injury. Am J Physiol Heart Circ Physiol. 2013;304:H369-H381 doi: 10.1152/ajpheart.00446.2012
45. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13:251-262 doi: 10.1038/nrm3311
46. Kim JE, Sung JY, Woo CH, Kang YJ, Lee KY, Kim HS, Kwun WH, Choi HC. Cilostazol inhibits vascular smooth muscle cell proliferation and reactive oxygen species production through activation of AMP-activated protein kinase induced by heme oxygenase-1. Korean J Physiol Pharmacol. 2011;15:203-210 doi: 10.4196/kjpp.2011.15.4.203
47. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med. 2001;7:48-52 doi: 10.1038/83336
48. Rivera J, Lozano ML, Navarro-Nunez L, Vicente V. Platelet receptors and signaling in the dynamics of thrombus formation. Haematologica. 2009;94:700-711 doi: 10.3324/haematol.2008.003178
49. Savage B, Cattaneo M, Ruggeri ZM. Mechanisms of platelet aggregation. Curr Opin Hematol. 2001;8:270-276
50. van Zanten GH, Heijnen HF, Wu Y, Schut-Hese KM, Slootweg PJ, de Groot PG, Sixma JJ, Nieuwland R. A fifty percent reduction of platelet surface glycoprotein Ib does not affect platelet adhesion under flow conditions. Blood. 1998;91:2353-2359
51. Akrawinthawong K, Park JW, Piknova B, Sibmooh N, Fucharoen S, Schechter AN. A flow cytometric analysis of the inhibition of platelet reactivity due to nitrite reduction by deoxygenated erythrocytes. PLoS One. 2014;9:e92435 doi: 10.1371/journal.pone.0092435
52. Ali FY, Hall MG, Desvergne B, Warner TD, Mitchell JA. PPARbeta/delta agonists modulate platelet function via a mechanism involving PPAR receptors and specific association/repression of PKCalpha-brief report. Arterioscler Thromb Vasc Biol. 2009;29:1871-1873 doi: 10.1161/ATVBAHA.109.193367
53. Youn YJ, Lee JW, Ahn SG, et al. Study design and rationale of "a multicenter, open-labeled, randomized controlled trial comparing three 2nd-generation drug-eluting stents in real-world practice" (CHOICE trial). Am Heart J. 2013;166:224-229 doi: 10.1016/j.ahj.2013.04.014
54. Webster MW, Ormiston JA. Drug-eluting stents and late stent thrombosis. Lancet. 2007;370:914-915 doi: 10.1016/S0140-6736(07)61424-X
55. Wessely R, Blaich B, Belaiba RS, Merl S, Gorlach A, Kastrati A, Schomig A. Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Implications for local drug delivery. Thromb Haemost. 2007;97:1003-1012
56. Kakade S, Mani G. A comparative study of the effects of vitamin C, sirolimus, and paclitaxel on the growth of endothelial and smooth muscle cells for cardiovascular medical device applications. Drug Des Devel Ther. 2013;7:529-544 doi: 10.2147/DDDT.S45162
57. Virmani R, Kolodgie FD, Farb A, Lafont A. Drug eluting stents: are human and animal studies comparable? Heart. 2003;89:133-138
|
Language: | English.
|
Document Type: | Basic Sciences.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 1079-5642
|
NLM Journal Code: | 9505803, B89
|
DOI Number: | https://dx.doi.org/10.1161/ATVBA...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|